ICRA reaffirmed Natco Pharma’s ratings across facilities with a stable outlook, including ₹930 crore fund-based, ₹120 crore non-fund-based limits, ₹100 crore unallocated, ₹400 crore term loan, and ₹400 crore commercial paper.
AI Assistant
Natco Pharma Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.